Evidence map›Paper›PMID 30811293›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Ian W Flinn, Richard van der Jagt, Brad Kahl, Peter Wood, Tim Hawkins, David MacDonald, David Simpson, Kathryn Kolibaba, Samar Issa, Julie Chang and 4 more

3 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 170 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 6 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00877006 phase3completednot on this map

An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

TypeinterventionalSponsorTeva Branded Pharmaceutical Products R&D, Inc.Ran2009 to 2012Enrolled447ConditionsNon-Hodgkin's Lymphoma, Mantle Cell LymphomaArmsbendamustine, rituximab, vincristine, prednisone, cyclophosphamide
NCT04943302 phase2withdrawnnot on this mapstarted 2022, after this paper: background citation

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

TypeinterventionalSponsorTufts Medical CenterRan2022 to 2026Enrolled0ConditionsAmyloidosis, Light Chain (AL) AmyloidosisArmsBendamustine Hydrochloride, Isatuximab
NCT07609446 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma: A Prospective, Multicenter, Phase II Study

Typeobservational_patient_registrySponsorThe First Affiliated Hospital of Soochow UniversityRan2026 to 2027Enrolled30ConditionsIndolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell LymphomaArmsPomalidomide
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 6 syntheses or guidelines pooled it, 295 citations in OpenAlex.

  1. Guideline
  2. [The guideline for the diagnosis and treatment of marginal zone lymphoma in China (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Guideline
  3. Pooled it
  4. [Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Guideline
  5. Pooled it
  6. [Chinese guidelines for diagnosis and treatment of follicular lymphoma (2020)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 4 countries.

Ian W Flinn1 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
Richard van der Jagt2 Ottawa Hospital, Ottawa, Ontario, Canada.
Brad Kahl3 Washington University School of Medicine, St Louis, MO.
Peter Wood4 Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Tim Hawkins5 Auckland City Hospital, Auckland, New Zealand.
David MacDonald6 Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
David Simpson7 North Shore Hospital, Auckland, New Zealand.
Kathryn Kolibaba8 US Oncology Research, Vancouver, WA.
Samar Issa9 Middlemore Hospital, Auckland, New Zealand.
Julie Chang10 University of Wisconsin Hospitals and Clinics, Madison, WI.
Judith Trotman11 Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia.
Doreen Hallman12 Teva Global Clinical Operations, Malvern, PA.
Ling Chen13 Teva Biometrics Operations, Malvern, PA.
John M Burke14 US Oncology Research, The Woodlands, TX.
Auckland City Hospital · NZConcord Repatriation General Hospital · AUMiddlemore Hospital · NZNorth Shore Hospital · NZOttawa Hospital · CAPrincess Alexandra Hospital · AUQueen Elizabeth II Health Sciences Centre · CASarah Cannon · USThe US Oncology Network · USUW Health University Hospital · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma. This publication provides long-term follow-up data. PATIENTS AND

methodsPatients were monitored for a minimum of 5 years after completion of study treatment for the time-to-event end points of progression-free survival (PFS), event-free survival, duration of response, and overall survival per investigator assessment. Data on the number of patients who received second-line anticancer treatment and the occurrence of other malignancies were also collected.

resultsThe medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment group and 55.8% in the R-CHOP/R-CVP group. The difference in PFS was considered significant with a hazard ratio of 0.61 (95% CI, 0.45 to 0.85;

conclusionOverall, BR demonstrated better long-term disease control than R-CHOP/R-CVP and should be considered as a first-line treatment option for patients with indolent and mantle-cell lymphoma.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCyclophosphamideDoxorubicinHumansLymphoma, Mantle-CellLymphoma, Non-HodgkinPrednisoneProgression-Free SurvivalProportional Hazards ModelsRituximabSurvival RateVincristineBendamustine HydrochlorideCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolR-CVP protocolRituximabVincristine

Identifiers

PMID30811293
PMCPMC6494265
OpenAlexW2917537905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.